GlycoMimetics Company Insiders

GLYC Stock  USD 0.28  0.01  3.70%   
About 84 percent of GlycoMimetics' insiders are selling. The analysis of the overall insider sentiment regarding GlycoMimetics suggests that quite a large number of insiders are terrified. GlycoMimetics employs about 4 people. The company is managed by 11 executives with a total tenure of roughly 47 years, averaging almost 4.0 years of service per executive, having 0.36 employees per reported executive.
Rachel King  CEO
President CEO, Founder, Director
Armand Girard  President
Senior Vice President Strategy and Corporate Development

Insider Sentiment 16

 Mostly Selling

 
Selling
 
Buying

Latest Trades

2024-08-07Public Equities L.P. InvusDisposed 61488 @ 0.18View
2024-08-05Public Equities L.P. InvusDisposed 164523 @ 0.19View
2024-08-01Public Equities L.P. InvusDisposed 63564 @ 0.22View
2024-07-29Public Equities L.P. InvusDisposed 363949 @ 0.24View
2024-07-26Public Equities L.P. InvusDisposed 258335 @ 0.24View
2024-06-20Edwin RockAcquired 190000 @ 0.25View
Monitoring GlycoMimetics' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
  
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in GlycoMimetics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.
For information on how to trade GlycoMimetics Stock refer to our How to Trade GlycoMimetics Stock guide.

GlycoMimetics Management Team Effectiveness

The company has return on total asset (ROA) of (0.7204) % which means that it has lost $0.7204 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.7325) %, meaning that it created substantial loss on money invested by shareholders. GlycoMimetics' management efficiency ratios could be used to measure how well GlycoMimetics manages its routine affairs as well as how well it operates its assets and liabilities. As of March 19, 2025, Return On Tangible Assets is expected to decline to -0.98. The current year's Return On Capital Employed is expected to grow to -7.16. At present, GlycoMimetics' Non Currrent Assets Other are projected to increase significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 11.6 B, whereas Non Current Assets Total are forecasted to decline to 0.00.
As of March 19, 2025, Common Stock Shares Outstanding is expected to decline to about 35.6 M. In addition to that, Net Loss is expected to decline to about (44.1 M)

GlycoMimetics Workforce Comparison

GlycoMimetics is rated below average in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 1,059. GlycoMimetics adds roughly 4.0 in number of employees claiming only tiny portion of equities under Health Care industry.

GlycoMimetics Insider Trading

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific GlycoMimetics insiders, such as employees or executives, is commonly permitted as long as it does not rely on GlycoMimetics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, GlycoMimetics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

GlycoMimetics Notable Stakeholders

A GlycoMimetics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as GlycoMimetics often face trade-offs trying to please all of them. GlycoMimetics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting GlycoMimetics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Rachel KingPresident CEO, Founder, DirectorProfile
Harout SemerjianPresident CEOProfile
Armand GirardSenior Vice President Strategy and Corporate DevelopmentProfile
Brian HahnCFO and Principal Accounting OfficerProfile
John MagnaniChief Scientific Officer, VP and DirectorProfile
Edwin MDSenior OfficerProfile
Chinmaya RathSenior OfficerProfile
Stephanie CPAVice AccountingProfile
Bruce JohnsonSenior OfficerProfile
Shantha TyavanagimattSenior OperationsProfile
Christian DinneenLongGeneral SecretaryProfile

About GlycoMimetics Management Performance

The success or failure of an entity such as GlycoMimetics often depends on how effective the management is. GlycoMimetics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of GlycoMimetics management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the GlycoMimetics management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last ReportedProjected for Next Year
Return On Tangible Assets(0.94)(0.98)
Return On Capital Employed(7.54)(7.16)
Return On Assets(0.94)(0.98)
Return On Equity(1.10)(1.16)
Please note, the presentation of GlycoMimetics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, GlycoMimetics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of GlycoMimetics' management manipulating its earnings.

GlycoMimetics Workforce Analysis

Traditionally, organizations such as GlycoMimetics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare GlycoMimetics within its industry.

GlycoMimetics Manpower Efficiency

Return on GlycoMimetics Manpower

Revenue Per Employee0.0
Revenue Per Executive0.0
Net Loss Per Employee9.5B
Net Loss Per Executive3.4B
Working Capital Per Employee1.3M
Working Capital Per Executive483.1K

Complementary Tools for GlycoMimetics Stock analysis

When running GlycoMimetics' price analysis, check to measure GlycoMimetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GlycoMimetics is operating at the current time. Most of GlycoMimetics' value examination focuses on studying past and present price action to predict the probability of GlycoMimetics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GlycoMimetics' price. Additionally, you may evaluate how the addition of GlycoMimetics to your portfolios can decrease your overall portfolio volatility.
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Transaction History
View history of all your transactions and understand their impact on performance
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals